Search

Emily Shiao-Chie Lin

from San Jose, CA
Age ~64

Emily Lin Phones & Addresses

  • San Jose, CA
  • Highland Park, NJ
  • 29 Forest Ave, Bridgewater, NJ 08807
  • 301 Wicklow Way, Bridgewater, NJ 08807 (908) 253-0310
  • 30 Cedar Ln APT D, Highland Park, NJ 08904

Work

Position: Professional/Technical

Education

Degree: Associate degree or higher

Professional Records

Lawyers & Attorneys

Emily Lin Photo 1

Emily Lin - Lawyer

View page
Office:
Tsar & Tsai Law Firm
Specialties:
Biotechnology
Chemicals and Chemistry
Patents
ISLN:
921256326
University:
National Central University, B.S., 2004; National Central University, B.S., 2004; National Central University, M.S., 2005; National Central University, M.S., 2005

Medicine Doctors

Emily Lin Photo 2

Emily Henghuey Lin

View page
Specialties:
Family Medicine
Education:
University of Michigan Medical School (1994)
Emily Lin Photo 3

Emily Henghuey Lin

View page
Specialties:
Family Medicine
Education:
(1994)
Emily Lin Photo 4

Emily Meiyu Lin, Fremont CA

View page
Specialties:
Optometrist
Address:
46324 Warm Springs Blvd, Fremont, CA 94539

Resumes

Resumes

Emily Lin Photo 5

Emily Lin Sunnyvale, CA

View page
Work:
ISE Labs Inc. / ASE Group

Sep 2012 to 2000
Sales Account Manager

ISE Labs Inc. / ASE Group
Fremont, CA
Aug 2011 to Aug 2012
Sales Support

Taiwanese Chinese Student Society
Davis, CA
Sep 2010 to Jun 2011
VP of Administration

Infinitel Wireless
Cupertino, CA
Jun 2006 to Aug 2010
Sales Representative

Education:
University of California
Davis, CA
2007 to 2011
Bachelor of Arts in Economics, Japanese double major

Skills:
Fluent in English and Mandarin Chinese, Conversational Japanese. Technical: Microsoft Word, Excel, PowerPoint, Outlook, Salesforce CRM

Business Records

Name / Title
Company / Classification
Phones & Addresses
Emily Lin
Treasurer
Broway Communications Co., Ltd
17896 Columbia Dr, Hayward, CA 94552

Publications

Us Patents

Nucleated Red Blood Cell Analysis System And Method

View page
US Patent:
20120282599, Nov 8, 2012
Filed:
Apr 26, 2012
Appl. No.:
13/456738
Inventors:
Jiong Wu - Los Gatos CA, US
Marilou Coleman - Newark CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US
Emily H. Lin - Cupertino CA, US
International Classification:
C12M 1/42
G01N 21/64
US Classification:
435 61, 4352872
Abstract:
Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

High Efficiency Methods For Combined Immunocytochemistry And In-Situ Hybridization

View page
US Patent:
6524798, Feb 25, 2003
Filed:
Jun 12, 2000
Appl. No.:
09/592120
Inventors:
Simon Goldbard - San Jose CA
Tsai-Hsia Hong - San Mateo CA
Michael A. Zoccoli - Moraga CA
Emily Lin - San Jose CA
Assignee:
Applied Imaging Corporation - Santa Clara CA
International Classification:
G01N 3353
US Classification:
435 6, 435 71, 435 75, 435 79, 536 2431, 536 2532
Abstract:
The invention provides a high efficiency method for combined immunocytochemistry and in situ hybridization. In one aspect, the method is used to simultaneously determining a cell phenotype and genotype by contacting a cell with an antigen-specific antibody bound to a ligand, contacting the cell with polynucleotide probe to form a complex of the probe and a nucleic acid in the cell, contacting the cell with a detectably labeled anti-ligand, and detecting the polynucleotide-probe complex and the anti-ligand-ligand complex. The presence of the anti-ligand is correlated with the presence of the antigen and the presence of the probe-nucleic acid complex is correlated with the presence of the nucleic acid in the cell.

Cellular Analysis Of Body Fluids

View page
US Patent:
20210130866, May 6, 2021
Filed:
Aug 25, 2020
Appl. No.:
17/002089
Inventors:
- Abbott Park IL, US
Emily H. Lin - Cupertino CA, US
Jihping Yang - Palo Alto CA, US
International Classification:
C12Q 1/04
G01N 33/50
Abstract:
Herein is provided a simple, reliable and accurate method for cellular analysis on hematology analyzers. In various aspects, the methods provide separation and/or differentiation between red blood cells (RBCs) and white blood cells (WBCs) by utilizing a fluorescent dye to selectively stain WBCs such that they emit stronger fluorescence signals. The method provides optimal detection limits on WBCs and RBCs, thereby allowing analysis of samples with sparse cellular concentrations. As few as one reagent may be used to prepare a single dilution for body fluid analysis, in order to simplify the body fluid analysis. Minimal damage to WBCs is attained using the lysis-free approach described in aspects of the disclosure.

Nucleated Red Blood Cell Analysis System And Method

View page
US Patent:
20200141858, May 7, 2020
Filed:
Oct 15, 2019
Appl. No.:
16/653489
Inventors:
- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US
International Classification:
G01N 15/14
G01N 33/80
G01N 21/64
G01N 33/49
Abstract:
Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

Automated Body Fluid Analysis

View page
US Patent:
20190204301, Jul 4, 2019
Filed:
Sep 7, 2017
Appl. No.:
16/330289
Inventors:
- Abbott Park IL, US
Emily H. Lin - Cupertino CA, US
Jiong Wu - Los Gatos CA, US
International Classification:
G01N 33/50
G01N 33/52
Abstract:
Methods, devices, and systems for automated cellular analysis of a body fluid sample are disclosed. The methods, devices, and systems apply watershed transform to data, generated by flowing a body fluid sample through a flow cytometer, to determine threshold(s) to be used for analysis of the data.

Cellular Analysis Of Body Fluids

View page
US Patent:
20180334699, Nov 22, 2018
Filed:
May 14, 2018
Appl. No.:
15/979230
Inventors:
- Abbott Park IL, US
Emily H. Lin - Cupertino CA, US
Jihping Yang - Palo Alto CA, US
International Classification:
C12Q 1/04
G01N 33/50
Abstract:
Herein is provided a simple, reliable and accurate method for cellular analysis on hematology analyzers. In various aspects, the methods provide separation and/or differentiation between red blood cells (RBCs) and white blood cells (WBCs) by utilizing a fluorescent dye to selectively stain WBCs such that they emit stronger fluorescence signals. The method provides optimal detection limits on WBCs and RBCs, thereby allowing analysis of samples with sparse cellular concentrations. As few as one reagent may be used to prepare a single dilution for body fluid analysis, in order to simplify the body fluid analysis. Minimal damage to WBCs is attained using the lysis-free approach described in aspects of the disclosure.

Nucleated Red Blood Cell Analysis System And Method

View page
US Patent:
20180128732, May 10, 2018
Filed:
Sep 14, 2017
Appl. No.:
15/704974
Inventors:
- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US
International Classification:
G01N 15/14
G01N 21/64
G01N 33/49
G01N 33/80
G01N 15/00
G01N 15/10
Abstract:
Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

Nucleated Red Blood Cell Analysis System And Method

View page
US Patent:
20160018312, Jan 21, 2016
Filed:
Jul 24, 2015
Appl. No.:
14/808720
Inventors:
- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US
International Classification:
G01N 15/14
G01N 21/64
G01N 33/49
Abstract:
Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.
Emily Shiao-Chie Lin from San Jose, CA, age ~64 Get Report